LFCR lifecore.com: Koefisien utang jangka dawa marang modal

This daily price chart for Lifecore Biomedical (LFCR) illustrates the asset's dynamics, with a value of 8.98. Lifecore Biomedical (LFCR) serves as a CDMO partner for biotech startups, maintaining a leadership position in hyaluronic acid purification. The company is currently scaling the production of sterile injectables while renegotiating B2B contracts. Stable demand in orthopedics and ophthalmology renders these services independent of economic crises, ensuring resilience.

LFCR - Utang jangka dawa marang ekuitas lifecore.com ing rentang 28.04.2023 - 28.10.2026

Rincian metrik komprehensif lan analitis Lifecore Biomedical Inc. (LFCR)

- rega lan prakiraan konsensus rega:

Bagan kutipan Lifecore|LFCR - Prakiraan konsensus analis

- data kapitalisasi pasar:

Nilai pasar Lifecore Biomedical, Inc.|LFCR - Nilai Perusahaan

- data kapitalisasi buku:

Nilai Buku saben Saham Lifecore Biomedical|LFCR - Nilai Buku Perusahaan|Nilai Pasar marang Nilai Buku lifecore.com|LFCR - Aset Agregat Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas Lifecore Biomedical|LFCR - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Lifecore|LFCR - Gunggung utang perusahaan|Rasio utang marang aset resik Lifecore Biomedical, Inc.

Analisis wiwitan perusahaan:LFCR lifecore.com

This indicator reflects the ratio of liabilities with a maturity of over one year to equity, determining the degree of financial leverage and the stability of the business's solvency. By analyzing the change in long-term debt to equity, an investor can assess how effectively the recovery of sterile injectables contract manufacturing at Lifecore Biomedical (LFCR) offsets the debt burden incurred during the period of restructuring and reporting delays.

Pesaing utama